Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Y-mabs Therapeutics Inc.
Headquarters: New York, NY, United States of America
Website: http://www.ymabs.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Michael Rossi
Number Of Employees: 107
Enterprise Value: $280,681,772
PE Ratio: -7.06
Exchange/Ticker 1: NASDAQ:YMAB
Exchange/Ticker 2: N/A
Latest Market Cap: $213,882,096
BioCentury | Jul 3, 2024
Management Tracks
CSO Kilty replaces Weir as Sitryx CEO
Plus: Y-mAbs hires Peter Pfreundschuh as CFO, and updates from LIfT,
BioCentury | Jun 5, 2024
Management Tracks
Sanofi vet Frank Nestle joins Deerfield as partner, CEO of 3DC
Plus: Lilly CFO Anat Ashkenazi leaving for Alphabet, and updates from Y-mAbs, Danaher and more
BioCentury | Mar 15, 2024
Management Tracks
CFO Jeff Trigilio leaves Cullinan
Plus: CFO Bo Kruse resigns at Y-mAbs, and updates from Endeavor, Nuclera and 4P-Pharma
BioCentury | Dec 21, 2023
Data Byte
GSK licenses second ADC from China-based Hansoh in two months
The deals mark the eighth and ninth in past five years for programs targeting PD-L1 family members B7-H3, B7-H4
BioCentury | Dec 1, 2023
Product Development
Radiopharmaceuticals’ multi-dimensional next wave
Target, ligand and radioisotope choices fuel the growing field
BioCentury | Oct 19, 2023
Management Tracks
Y-mAbs names Rossi CEO
Plus: Cargo hires Laport as CMO and updates from SVB and Genascence
BioCentury | Dec 17, 2022
Data Byte
CHMP recommends approval of CSL’s gene therapy for hemophilia B
December highlights include AstraZeneca’s two CTLA-4 programs, negative opinion on Y-mAbs’ CD276 mAb
BioCentury | Dec 2, 2022
Regulation
Dec. 1 Quick Takes: FDA approves Rigel, Forma therapy for AML
Plus: Pfizer, Roivant form new unit around ulcerative colitis target, China’s Trinomab raises over $100M and updates from Nordic-APIM, Nectin, NIST and more
BioCentury | Nov 2, 2022
Data Byte
At least seven PDUFA dates on deck in November
Agents up for their first approval include Apellis’ geographic atrophy therapy and Provention’s diabetes interception program
BioCentury | Oct 28, 2022
Product Development
Oct. 28 Quick Takes: Gilead returns to $100B market cap on strong earnings
Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more
Items per page:
1 - 10 of 36